These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 26309144)
1. Human Papillomavirus vaccination in general practice in France, three years after the implementation of a targeted vaccine recommendation based on age and sexual history. Thierry P; Lasserre A; Rossignol L; Kernéis S; Blaizeau F; Stheneur C; Blanchon T; Levy-Bruhl D; Hanslik T Hum Vaccin Immunother; 2016; 12(2):528-33. PubMed ID: 26309144 [TBL] [Abstract][Full Text] [Related]
2. Eligibility and willingness of first-year students entering university to participate in a HPV vaccination catch-up program. Mehu-Parant F; Rouzier R; Soulat JM; Parant O Eur J Obstet Gynecol Reprod Biol; 2010 Feb; 148(2):186-90. PubMed ID: 19926199 [TBL] [Abstract][Full Text] [Related]
3. [HPV prophylactic vaccine coverage and factors impacting its practice among students and high school students in Marseilles' area]. Baudoin A; Sabiani L; Oundjian F; Tabouret E; Agostini A; Courbière B; Boubli L; Carcopino X J Gynecol Obstet Biol Reprod (Paris); 2015 Feb; 44(2):126-35. PubMed ID: 24703591 [TBL] [Abstract][Full Text] [Related]
4. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges. Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574 [TBL] [Abstract][Full Text] [Related]
5. Human Papillomavirus awareness, knowledge and vaccine acceptance: a survey among 18-25 year old male and female vocational school students in Berlin, Germany. Blödt S; Holmberg C; Müller-Nordhorn J; Rieckmann N Eur J Public Health; 2012 Dec; 22(6):808-13. PubMed ID: 22199161 [TBL] [Abstract][Full Text] [Related]
6. Age impact on human papillomavirus vaccination in France in 2014: A study from the National Health Insurance Database. Héquet D; Pouget N; Estevez JP; Robain M; Rouzier R Bull Cancer; 2015 Nov; 102(11):892-7. PubMed ID: 26526386 [TBL] [Abstract][Full Text] [Related]
7. Cervical cancer risk perceptions, sexual risk behaviors and sexually transmitted infections among Bivalent Human Papillomavirus vaccinated and non-vaccinated young women in Uganda - 5 year follow up study. Kumakech E; Andersson S; Wabinga H; Musubika C; Kirimunda S; Berggren V BMC Womens Health; 2017 Jun; 17(1):40. PubMed ID: 28576143 [TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus vaccines in Picardy, France: coverage and correlation with socioeconomic factors. Ganry O; Bernin-Mereau AS; Gignon M; Merlin-Brochard J; Schmit JL Rev Epidemiol Sante Publique; 2013 Oct; 61(5):447-54. PubMed ID: 24016739 [TBL] [Abstract][Full Text] [Related]
9. Providers' beliefs about the effectiveness of the HPV vaccine in preventing cancer and their recommended age groups for vaccination: Findings from a provider survey, 2012. Berkowitz Z; Malone M; Rodriguez J; Saraiya M Prev Med; 2015 Dec; 81():405-11. PubMed ID: 26598805 [TBL] [Abstract][Full Text] [Related]
10. Factors associated with Human Papilloma Virus (HPV) vaccine recommendation by physicians in Lebanon, a cross-sectional study. Abi Jaoude J; Khair D; Dagher H; Saad H; Cherfan P; Kaafarani MA; Jamaluddine Z; Ghattas H Vaccine; 2018 Nov; 36(49):7562-7567. PubMed ID: 30420044 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France. Heard I; Tondeur L; Arowas L; Demazoin M; Falguières M; Parent Du Chatelet I; J Infect Dis; 2017 Mar; 215(5):757-763. PubMed ID: 28011911 [TBL] [Abstract][Full Text] [Related]
12. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook. Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782 [TBL] [Abstract][Full Text] [Related]
13. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium. Demarteau N; Van Kriekinge G; Simon P Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952 [TBL] [Abstract][Full Text] [Related]
14. HPV vaccination coverage in French girls attending middle and high schools: a declarative cross sectional study in the department of Côte d'Or. Bertaut A; Chavanet P; Aho S; Astruc K; Douvier S; Fournel I Eur J Obstet Gynecol Reprod Biol; 2013 Oct; 170(2):526-32. PubMed ID: 23953913 [TBL] [Abstract][Full Text] [Related]
15. Sex of Sexual Partners and Human Papillomavirus Vaccination Among U.S. Girls and Women. Agénor M; McCauley HL; Peitzmeier SM; Haneuse S; Gordon AR; Potter J; Austin SB Am J Prev Med; 2016 Mar; 50(3):318-327. PubMed ID: 26585049 [TBL] [Abstract][Full Text] [Related]
16. Inter-state variation in human papilloma virus vaccine coverage among adolescent girls in the 50 US states, 2007. Kramer MR; Dunlop AL Matern Child Health J; 2012 Apr; 16 Suppl 1():S102-10. PubMed ID: 22453332 [TBL] [Abstract][Full Text] [Related]
17. HPV vaccination among French girls and women aged 14-23 years and the relationship with their mothers' uptake of Pap smear screening: a study in general practice. Lutringer-Magnin D; Cropet C; Barone G; Canat G; Kalecinski J; Leocmach Y; Vanhems P; Chauvin F; Lasset C Vaccine; 2013 Oct; 31(45):5243-9. PubMed ID: 24012565 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G; Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922 [TBL] [Abstract][Full Text] [Related]
19. Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries. Baussano I; Lazzarato F; Ronco G; Dillner J; Franceschi S Int J Cancer; 2013 Oct; 133(8):1876-81. PubMed ID: 23564420 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras. Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]